Amicus Therapeutics share price today
(NASDAQ: FOLD)

Name: Amicus Therapeutics Share Price Today (NASDAQ: FOLD) - Amicus Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Amicus Therapeutics share price is $9.65 & ₹834.63 as on 24 Jan 2025, 2.30 'hrs' IST

$9.65

▲

0.11

(1.15%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Amicus Therapeutics share price in Dollar and Rupees. Guide to invest in Amicus Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Amicus Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Amicus Therapeutics share price movements

Today's Low: $9.41
Today's High: $9.73
$9.65
2.49%
Downside
Day's Volatility :3.24%
Upside
0.77%
52 Weeks Low: $8.79
52 Weeks High: $14.03
$9.65
8.96%
Downside
52 Weeks Volatility :37.38%
Upside
31.22%

Amicus Therapeutics Returns

Period	Amicus Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-18.39%	-5.5%	0.0%
6 Months	-6.29%	-4.3%	0.0%
1 Year	-24.53%	1.6%	0.0%
3 Years	0.42%	9.8%	-11.0%

Amicus Therapeutics Key Statistics

in dollars & INR

Previous Close	$9.54
Open	$9.45
Today's High	$9.725
Today's Low	$9.41
Market Capitalization	$2.9B
Today's Volume	$1.6M
52 Week High	$14.03
52 Week Low	$8.785
Revenue TTM	$493.7M
EBITDA	$23.1M
Earnings Per Share (EPS)	$-0.34
Profit Margin	-21.21%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-67.09%

How to invest in Amicus Therapeutics Stock (FOLD) from India?

It is very easy for Indian residents to invest directly in Amicus Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Amicus Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Amicus Therapeutics or FOLD on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Amicus Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Amicus Therapeutics shares which would translate to 0.090 fractional shares of Amicus Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Amicus Therapeutics, in just a few clicks!

Returns in Amicus Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Amicus Therapeutics investment value today

Current value as on today

₹80,399

Returns

₹19,601

(-19.6%)

Returns from Amicus Therapeutics Stock

₹23,655 (-23.66%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Amicus Therapeutics

-57%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Amicus Therapeutics on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -57% less investors are searching Amicus Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Amicus Therapeutics

Vanguard Group Inc
9.64%
Perceptive Advisors LLC
9.39%
BlackRock Inc
8.74%
Wellington Management Company LLP
8.02%
venBio Select Advisor LLC
7.76%
William Blair Investment Management, LLC
5.22%

Analyst Recommendation on Amicus Therapeutics

Buy

76%Buy

23%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Amicus Therapeutics(by analysts ranked 0 to 5 stars)

Based on 17 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Amicus Therapeutics

What analysts predicted

Upside of 77.11%

Target:

$17.09

Current:

$9.65

Insights on Amicus Therapeutics

Price Movement
In the last 1 month, FOLD stock has moved down by -3.0%
Increasing Revenue
Revenue is up for the last 3 quarters, 110.40M → 141.51M (in $), with an average increase of 11.7% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -48.41M → -6.72M (in $), with an average increase of 170.9% per quarter
FOLD vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 40.5% return, outperforming this stock by 63.9%
FOLD vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 89.3%
Price to Sales
ForFOLD every $1 of sales, investors are willing to pay $5.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.1 for every $1 of sales.

Amicus Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$91.2M	↑ 147.08%
Net Income	$-349.0M	↑ 22.88%
Net Profit Margin	-382.48%	↑ 386.55%

	FY19	Y/Y Change
Revenue	$182.2M	↑ 99.72%
Net Income	$-356.4M	↑ 2.12%
Net Profit Margin	-195.56%	↑ 186.92%

	FY20	Y/Y Change
Revenue	$260.9M	↑ 43.16%
Net Income	$-276.9M	↓ 22.32%
Net Profit Margin	-106.12%	↑ 89.44%

	FY21	Y/Y Change
Revenue	$305.5M	↑ 17.11%
Net Income	$-250.5M	↓ 9.53%
Net Profit Margin	-81.98%	↑ 24.14%

	FY22	Y/Y Change
Revenue	$329.2M	↑ 7.76%
Net Income	$-236.6M	↓ 5.55%
Net Profit Margin	-71.85%	↑ 10.13%

	FY23	Y/Y Change
Revenue	$399.4M	↑ 21.3%
Net Income	$-151.6M	↓ 35.92%
Net Profit Margin	-37.96%	↑ 33.89%

	Q2 FY23	Q/Q Change
Revenue	$94.5M	↑ 9.54%
Net Income	$-43.2M	↓ 18.33%
Net Profit Margin	-45.75%	↑ 15.61%

	Q3 FY23	Q/Q Change
Revenue	$103.5M	↑ 9.52%
Net Income	$-21.6M	↓ 50.09%
Net Profit Margin	-20.85%	↑ 24.9%

	Q4 FY23	Q/Q Change
Revenue	$115.1M	↑ 11.19%
Net Income	$-33.8M	↑ 56.85%
Net Profit Margin	-29.41%	↓ 8.56%

	Q1 FY24	Q/Q Change
Revenue	$110.4M	↓ 4.07%
Net Income	$-48.4M	↑ 43.07%
Net Profit Margin	-43.86%	↓ 14.45%

	Q2 FY24	Q/Q Change
Revenue	$126.7M	↑ 14.73%
Net Income	$-15.7M	↓ 67.58%
Net Profit Margin	-12.39%	↑ 31.47%

	Q3 FY24	Q/Q Change
Revenue	$141.5M	↑ 11.72%
Net Income	$-6.7M	↓ 57.13%
Net Profit Margin	-4.75%	↑ 7.64%

	FY18	Y/Y Change
Profit	$76.8M	↑ 150.35%

	FY19	Y/Y Change
Profit	$160.3M	↑ 108.58%

	FY20	Y/Y Change
Profit	$229.8M	↑ 43.41%

	FY21	Y/Y Change
Profit	$271.0M	↑ 17.93%

	FY22	Y/Y Change
Profit	$290.6M	↑ 7.23%

	FY23	Y/Y Change
Profit	$362.0M	↑ 24.57%

	Q2 FY23	Q/Q Change
Profit	$85.4M	↑ 7.64%

	Q3 FY23	Q/Q Change
Profit	$93.6M	↑ 9.56%

	Q4 FY23	Q/Q Change
Profit	$101.6M	↑ 8.57%

	Q1 FY24	Q/Q Change
Profit	$94.7M	↓ 6.79%

	Q2 FY24	Q/Q Change
Profit	$113.2M	↑ 19.59%

	Q3 FY24	Q/Q Change
Profit	$128.2M	↑ 13.26%

	FY18	Y/Y Change
Operating Cash Flow	$-300.0M	↑ 39.2%
Investing Cash Flow	$-121.2M	↓ 29.22%
Financing Cash Flow	$450.8M	↑ 82.18%

	FY19	Y/Y Change
Operating Cash Flow	$-250.4M	↓ 16.52%
Investing Cash Flow	$95.2M	↓ 178.51%
Financing Cash Flow	$217.5M	↓ 51.75%

	FY20	Y/Y Change
Operating Cash Flow	$-233.3M	↓ 6.84%
Investing Cash Flow	$-13.6M	↓ 114.27%
Financing Cash Flow	$262.9M	↑ 20.85%

	FY21	Y/Y Change
Operating Cash Flow	$-202.5M	↓ 13.2%
Investing Cash Flow	$78.8M	↓ 680.02%
Financing Cash Flow	$212.1M	↓ 19.32%

	FY22	Y/Y Change
Operating Cash Flow	$-166.6M	↓ 17.74%
Investing Cash Flow	$92.3M	↑ 17.21%
Financing Cash Flow	$-7.5M	↓ 103.52%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-16.1M	↓ 10.71%
Investing Cash Flow	$50.0M	↑ 37.91%
Financing Cash Flow	$23.7M	↓ 402.53%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-38.3M	↑ 137.69%
Investing Cash Flow	$35.8M	↓ 28.47%
Financing Cash Flow	$37.6M	↑ 58.91%

Amicus Therapeutics Technicals Summary

Sell

Neutral

Buy

Amicus Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Amicus Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Amicus Therapeutics, Inc.	-2.35%	-6.29%	-24.53%	0.42%	7.49%
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Amicus Therapeutics, Inc.	NA	NA	-0.18	0.23	-0.67	0.01	NA	0.6
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Amicus Therapeutics, Inc.	Buy	$2.9B	7.49%	NA	-21.21%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

Amicus Therapeutics Dividend announcements

Amicus Therapeutics Earnings
Amicus Therapeutics’s price-to-earnings ratio stands at None
Read More

About Amicus Therapeutics

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Organization	Amicus Therapeutics
Employees	500
CEO	Mr. Bradley L. Campbell M.B.A.
Industry	Health Technology

Management People of Amicus Therapeutics

Name	Title
Mr. Bradley L. Campbell M.B.A.	CEO, President & Director
Mr. Simon Nicolas Reade Harford	Chief Financial Officer
Ms. Ellen S. Rosenberg J.D.	Chief Legal Officer & Corporate Secretary
Mr. David M. Clark	Chief People Officer
Dr. Jeffrey P. Castelli Ph.D.	Chief Development Officer
Ms. Samantha Prout	Chief Accounting Officer & Controller
Dr. Jill Weimer Ph.D.	Chief Science Officer
Mr. Andrew Faughnan	Senior Director of Investor Relations
Mr. Patrik S. Florencio Esq.	Global Chief Compliance & Risk Officer
Ms. Diana Moore	Head of Global Corporate Communications

Important FAQs about investing in Amicus Therapeutics (FOLD) from India :

What is Amicus Therapeutics share price today?

Amicus Therapeutics share price today stands at $9.65, Open: $9.45 ; Previous Close: $9.54 ; High: $9.73 ; Low: $9.41 ; 52 Week High: $14.03 ; 52 Week Low: $8.79. The stock opens at $9.45, after a previous close of $9.54. The stock reached a daily high of $9.73 and a low of $9.41, with a 52-week high of $14.03 and a 52-week low of $8.79.

Can Indians buy Amicus Therapeutics shares?

Yes, Indians can invest in the Amicus Therapeutics (FOLD) from India.

With INDmoney, you can buy Amicus Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Amicus Therapeutics at zero transaction cost.

How can I buy Amicus Therapeutics shares from India?

It is very easy to buy Amicus Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Amicus Therapeutics be purchased?

Yes, you can buy fractional shares of Amicus Therapeutics with INDmoney app.

What are the documents required to start investing in Amicus Therapeutics stocks?

To start investing in Amicus Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.